DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

An accomplished biotech and healthcare executive, Ms. Deptula-Hicks most recently served as Chief Financial Officer of F-star ...

The HERCULES study focused on the efficacy and safety of tolebrutinib in individuals with non-relapsing secondary progressive MS (nrSPMS) compared to a placebo. In August 2024, Abata Therapeutics ...

CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from ...

Alison Hood, General Counsel Ms. Hood is an experienced general counsel in the biotech and pharma sector. She was previously VP & Head of Legal, International at Aimmune Therapeutics, a position she ...

Multiple Key Leadership Appointments, Including Warner Biddle as CEO, Bringing Clinical, Commercial and Strategic Expertise in Cell Therapy Continuing to Advance Broad ...

Ms. Eastland is an accomplished biopharmaceutical executive with substantial leadership experience operating late-stage oncology companies. She previously served as Chief Executive Officer at Harpoon ...

Memorandum of Understanding has been signed NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc ...

Q3 2024 Earnings Call Transcript November 7, 2024 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

See Table 1 for currently approved disease-modifying MS therapeutics. Mathias Buttmann, MD, Julius-Maximilians University, Department of Neurology, Josef-Schneider-Str. 11, 97080 Würzburg ...

Scientists say that blocking a protein called DLK could help protect against neurodegeneration of demyelinated nerve cells in ...